Show simple item record

dc.contributor.authorSchroeder, BA
dc.contributor.authorLaFranzo, NA
dc.contributor.authorLaFleur, BJ
dc.contributor.authorGittelman, RM
dc.contributor.authorVignali, M
dc.contributor.authorZhang, S
dc.contributor.authorFlanagan, KC
dc.contributor.authorRytlewski, J
dc.contributor.authorRiolobos, L
dc.contributor.authorSchulte, BC
dc.contributor.authorKim, TS
dc.contributor.authorChen, E
dc.contributor.authorSmythe, KS
dc.contributor.authorWagner, MJ
dc.contributor.authorMantilla, JG
dc.contributor.authorCampbell, JS
dc.contributor.authorPierce, RH
dc.contributor.authorJones, RL
dc.contributor.authorCranmer, LD
dc.contributor.authorPollack, SM
dc.coverage.spatialEngland
dc.date.accessioned2022-09-13T09:55:30Z
dc.date.available2022-09-13T09:55:30Z
dc.date.issued2021-08-01
dc.identifierARTN e002812
dc.identifierjitc-2021-002812
dc.identifier.citationJournal for ImmunoTherapy of Cancer, 2021, 9 (8), pp. e002812 -en_US
dc.identifier.issn2051-1426
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5452
dc.identifier.eissn2051-1426
dc.identifier.eissn2051-1426
dc.identifier.doi10.1136/jitc-2021-002812
dc.description.abstractBACKGROUND: Dedifferentiated liposarcoma (DDLPS) is one of the most common soft tissue sarcoma subtypes and is devastating in the advanced/metastatic stage. Despite the observation of clinical responses to PD-1 inhibitors, little is known about the immune microenvironment in relation to patient prognosis. METHODS: We performed a retrospective study of 61 patients with DDLPS. We completed deep sequencing of the T-cell receptor (TCR) β-chain and RNA sequencing for predictive modeling, evaluating both immune markers and tumor escape genes. Hierarchical clustering and recursive partitioning were employed to elucidate relationships of cellular infiltrates within the tumor microenvironment, while an immune score for single markers was created as a predictive tool. RESULTS: Although many DDLPS samples had low TCR clonality, high TCR clonality combined with low T-cell fraction predicted lower 3-year overall survival (p=0.05). Higher levels of CD14+ monocytes (p=0.02) inversely correlated with 3-year recurrence-free survival (RFS), while CD4+ T-cell infiltration (p=0.05) was associated with a higher RFS. Genes associated with longer RFS included PD-1 (p=0.003), ICOS (p=0.006), BTLA (p=0.033), and CTLA4 (p=0.02). In a composite immune score, CD4+ T cells had the strongest positive predictive value, while CD14+ monocytes and M2 macrophages had the strongest negative predictive values. CONCLUSIONS: Immune cell infiltration predicts clinical outcome in DDLPS, with CD4+ cells associated with better outcomes; CD14+ cells and M2 macrophages are associated with worse outcomes. Future checkpoint inhibitor studies in DDLPS should incorporate immunosequencing and gene expression profiling techniques that can generate immune landscape profiles.en_US
dc.formatPrint
dc.format.extente002812 -
dc.languageeng
dc.language.isoengen_US
dc.publisherBMJ PUBLISHING GROUPen_US
dc.relation.ispartofJournal for ImmunoTherapy of Cancer
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/en_US
dc.subjectCD4-positive T-lymphocytesen_US
dc.subjectimmunityen_US
dc.subjectmacrophagesen_US
dc.subjectsarcomaen_US
dc.subjecttumor microenvironmenten_US
dc.subjectAdolescenten_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectCD4-Positive T-Lymphocytesen_US
dc.subjectCell Differentiationen_US
dc.subjectChilden_US
dc.subjectChild, Preschoolen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectInfanten_US
dc.subjectInfant, Newbornen_US
dc.subjectLiposarcomaen_US
dc.subjectMacrophagesen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectPatient Outcome Assessmenten_US
dc.subjectRetrospective Studiesen_US
dc.subjectYoung Adulten_US
dc.titleCD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes.en_US
dc.typeJournal Article
dcterms.dateAccepted2021-07-26
dc.date.updated2022-09-13T09:53:46Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1136/jitc-2021-002812en_US
rioxxterms.licenseref.startdate2021-08-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/34465597
pubs.issue8
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1136/jitc-2021-002812
pubs.volume9
dc.contributor.icrauthorJones, Robin
icr.provenanceDeposited by Mr Arek Surman on 2022-09-13. Deposit type is initial. No. of files: 1. Files: CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. .pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0/